Efficient collaboration and data sharing are essential prerequisites for improving efficiency, safety and outcomes in medicine. Current separation of clinical research and care creates a significant knowledge gap, especially in the case of complex diseases such as cancer, hampering research and slowing down the transfer of the latest research results to patient care. The momentum gained by initiatives focusing on these aspects indicates that under the right circumstances, the biomedical community is ready and willing to open up. However, main technological barriers concerning semantic interoperability, security and privacy need to be addressed to make this change possible. In this paper we describe our scalable, standards-based and open approach towards addressing these issues in the context of a large initiative with focus in oncology.
INTRODUCTION
Despite large investments in IT, the healthcare domain is currently unable to obtain the desired benefits in quality, safety and efficiency of care and to use those IT systems at their full potential. The lack of integration and of semantic interoperability among systems is a significant source of inefficiency, data inconsistencies, unnecessary costs and an unacceptably large number of medical errors. As the cost of healthcare in Europe becomes almost unaffordable, reducing expenses while significantly increasing the quality, safety and efficiency of care is a necessity. Furthermore, the pharmaceutical industry faces low recruitment rates of patients and extremely high costs of running clinical trials due to lack of interoperability and complex and inefficient study execution, while having a strong need to reduce research expenses and the time-to-market of new drugs.
Additionally, there is a widening knowledge gap between the care provided in top research clinical sites and standard care sites, resulting in large differences in treatments and outcomes. In this context, the need to bring the latest therapy options validated in clinical research to each and every hospital must be addressed before being able to significantly reduce the numbers of patients that receive suboptimal treatment (e.g. overtreatment, wrong dose, etc.), or the wrong treatment. There are currently very few mechanisms and formally established channels for transferring the best practices to clinicians and the current dissemination means are insufficient.
While the need to share and collaborate is increasingly being recognized, with large initiatives gaining significant support 1,2 , several technological issues limit progress: lack of semantic interoperability among systems in care and research, and concerns regarding security and privacy if those systems were to open up.
In this paper we describe our approach towards semantic interoperability, which will be implemented part of a large EU-funded initiative and deployed within a broad community of top European healthcare organizations that focus on research and care in oncology. We aim to enable seamless, secure, scalable and consistent linkage of healthcare information residing in EHR systems with information in clinical research information systems, such as clinical trial systems, supporting the two currently separated worlds of clinical research and clinical practice to connect and benefit from each other.
The remaining of the paper is structured as follows. Section 2 argues for the need to provide the appropriate technological solutions to enable semantic bi-directional linkage of clinical care and clinical research data. We also describe relevant applications in research and care that would benefit from a scalable and secure semantic interoperability solution. Our approach to semantic interoperability is described in Section 3. We also address the privacy and security needs related to sharing patient data across research and care, as described in Section 4. 
NEED FOR LINKING EHR AND CLINICAL TRIAL DATA
The need for integration of clinical care and clinical trial systems has been identified as a way to significantly improve the effectiveness and efficiency of clinical research (Ohmann, 2007) . We believe that such integration can also strongly benefit clinical care. Next to benefits concerning patient outcomes and safety, this integration has an important potential to bring along significant cost reduction. The current separation between clinical research and clinical care makes the detection of many serious patient safety issues difficult. Serious side effects (Oeffinger, 2009) , of therapy and drugs that appear outside a clinical trial either due to a low incidence or a late onset are very difficult to detect and to explain in the absence of a feedback loop from standard care to research.
Although having the potential to bring important benefits (Safran, 2007) , (Pakhomov, 2007) , the secondary use of care data for research, quality assurance and patient safety is still rarely supported. Main barriers to enabling secondary use of data are the lack of interoperability, common standards and terminologies, and challenges around data security and patient privacy.
The semantic bi-directional linkage of clinical research and clinical care systems will support many highly relevant applications in research and care, such as:  Supporting more effective and efficient execution of clinical research by allowing faster eligible patient identification and enrolment in clinical trials, and providing access -in a legally compliant and secure manner -to the large amounts of patient data collected in the EHR systems to be re-used in clinical research, for new hypotheses building and testing (e.g. to benefit rare diseases), study feasibility, as well as for epidemiology studies.  Enabling long term follow up of patients, beyond the end of a clinical trial.  Avoiding the current need for multiple data entry in the various clinical care and research systems during the execution of a study.  Allowing data mining of longitudinal EHR data for early detection of patient safety issues related to therapies and drugs that would not become manifest in a clinical trial either due to limited sample size or to limited trial duration, and eliminate duplicate reporting (in care and research) of identified serious side effects,  Supporting faster transfer of new research findings and guidelines to the clinical setting (from bench-to-bedside). Figure 1 depicts our gradual approach towards reaching semantic agreement among EHR and CT systems. We move away from the implementation heterogeneity of the local sources by building canonical models of the sources which will be mapped to our reference model and to the semantic core dataset (described in section 3.1).
The canonical models describe the data in the sources while making use of the semantics of the core dataset. Figure 2 presents the envisioned application services enabled by the desired linkage between the EHR and CT systems. 
SEMANTIC INTEROPERABILITY
Using the SemanticHEALTH classification (Stroetmann, 2009 ) of semantic interoperability (SIOp) we can observe that the current level of SIOp between CTs and EHRs is somewhere between level 0, i.e. no interoperability at all, and level 1 i.e. syntactic interoperability. The reason for this is the fact that these systems were designed as information silos in isolation, not foreseeing the benefits of mutual data exchange as laid out in the section above. In order to achieve the aforementioned benefits, we have to increase the SIOp level to at least 2b -bidirectional semantic interoperability of meaningful fragments, or even level 3 which requires full semantic interoperability, sharable context. It is however also recognized that due to the steep investments needed, the highest level of semantic interoperability should only be sought in specific areas with high potential for significant improvements.
The essential steps for achieving this SIOp improvement include the definition of sound information models describing the clinical trial systems, building on existing research results when possible (Weiler, 2007) . Electronic health records too need to be properly modelled; to that end we will adopt the appropriate state-of-the-art representation formalisms such as HL7 CDA, the openEHR Reference Model, ISO/EN 13606, etc.
Semantic Core Dataset
The foundation of the semantic interoperability layer will be the semantic core dataset comprising soundly defined and agreed-upon clinical structures consisting of standard-based concepts, their relationships, and quantification (e.g. archetypes using selected terminology concepts) that together sufficiently describe the semantics of the chosen clinical domain.
The semantics of the clinical terms should be captured by standard terminology systems such as SNOMED CT, ICD, LOINC. The scalability of the solution needs to be achieved by modularization and scoping, e.g. instead of aiming at inclusion of the complete SNOMED terminology (more than 300 thousand concepts) we identify a core subset that covers the chosen clinical domain. The main rationale here is that only a confined subset of relevant concepts from the clinical ontology will be needed for data extraction and reasoning in a given clinical context/domain while most of the remaining concepts would never be used by reasoning algorithms.
Such core dataset shall be validated both by clinical and knowledge engineering experts to assure proper coverage and soundness. In the process of identifying the core data set and the corresponding mapping tools, care will be taken to allow for easy extension of the core data set, should the inclusion of new concepts become necessary (e.g. a crossdomain linkage). Relying on well established and widely used existing terminology standards will facilitate extensible semantic interoperability towards third parties outside of the scope of the project. This approach is in line with the roadmap of SemanticHEALTH which lists identifying of sound semantic subsets of SNOMED covering a certain clinical domain as one of their priorities (Stroetmann, 2009) .
The core semantic data set will be validated in concrete use cases, for the different EHR and clinical trial systems available at the clinical care and clinical trial sites within the consortium. The semantic core dataset is an essential prerequisite to semantically-aware access to both EHR and Clinical trial data in a machine processable manner. Concepts in the dataset will have their unique identifiers, well understood meaning, as well as a set of synonyms they can be referred as. Multicenter clinical trials often span across several countries which introduces the problem of language heterogeneity between the CTs and EHRs as primary data capture. We plan to address this issue by offering a gradual approach, semiautomatically translating only those parts of the clinical ontology identified as the core semantic dataset, leveraging existing translations of known terminologies such as SNOMED CT. When no translation of the relevant standard terminologies exist in that language, we will work out together with the clinical experts a translation of the core dataset into the languages that are used for the primary data capture. Hence, translating (only) the selected semantic core dataset and not the entire clinical coding system enables a modular and scalable approach where the initial translation effort is limited in scope and delivers immediate benefits in increased semantic interoperability.
The Semantic Interoperability Platform
The canonical information models of the EHR and CT systems will be mapped to the semantic core dataset in order to guarantee a well defined meaning of various data elements across the entire platform. We will identify the requirements for mappings that bridge the semantic core data set with the information models representing the EHR systems and the clinical trial systems. These information models provide a canonical view, reflecting the content and the structure of the respective information management system. The proposed mapping formalism should be able to mitigate the foreseen structural and contextual differences between the semantic core dataset and the information models. We will use this formalism to instantiate the necessary schema-level mappings (Figure 4 , top) that will be executed by the semantic interoperability platform during the data extraction process. In order to facilitate the necessary data transformation among various information systems which need to interoperate, we deploy our semantic interoperability run-time platform (Figure 4 , middle). This platform will utilize the semantic core dataset as well as the schema-level mappings that link to the EHR and CT information models. The platform will be able to execute these mappings during the data extraction phase, instantiating thus the semantic concepts with patient data and/or clinical trial data. The semantic interoperability platform will be an essential software engine behind the application services, enabling linkage between the patient data in the EHR and the clinical trial systems. The platform itself is an instantiation of our reference service architecture blueprint and leverages the chosen reference model (RM) (Figure  4 , bottom).
SECURITY AND PRIVACY
The sensitive nature of health information and the harm that can be caused by its abuse is widely known. It needs no debate that the risk and impact of this abuse significantly increases when more information about individual patients is accumulated and is more frequently exchanged among different parties (caregivers, researchers, etc.). Specific legislation, regulations and ethical guidelines with respect to (patient) privacy have therefore been put in place at different levels (European, national and regional).
In this context, the capability to satisfy varying ethical concerns and ensure compliance to data protection legislation and regulations is fundamental to the success (viability in the long run) of any solution aiming to integrate health information on a large scale.
Our approach to this matter comprises the design of a comprehensive Data Protection Framework (DPF) which outlines the boundaries within which services (and organisations) are required to operate. The DPF brings "compliance by design" by combining both a governance framework (policies and procedures) and a set of technical implementations aimed at enforcing the latter. It implements the rules set by the relevant National and EU legislation and sector best practice policies (ethics). The framework not only manages and enforces rules defining "Who has access to what data for which purpose, and under what conditions", but also integrates solutions which enable access to otherwise unavailable data (a.o. Trusted Third Party supported de-identification).
Introducing a uniform layer (technical solutions integrated in a single governance framework) upon which applications can (and need to) build has already proven to be a successful approach (Claerhout, 2008) to efficiently deal with regulatory issues of large scale transnational sharing of medical and biological data in the clinical trial context. One of the things that the overall governance and security framework referenced above introduced was a novel practical solution (concept of "de-facto anonymous data") that covers the inherent issues tied to deidentification of individual person records (Li, 2007) . That work will serve as a basis for our DPF which needs to deal with the broader scope of bidirectional cross-domain interaction between the care and research domain.
Technically, the DPF will rely on (centralised) policy based authorization services to translate the legal rule sets into authorisation decisions for "access to" or "processing of" highly sensitive data over distributed resources. This approach ensures flexibility towards changing legislation and policies (and regional variations thereof).
To meet the specific requirements of the DPF, the authorisation system (both decision and enforcement parts) needs to support concepts such as "purpose of use" and "conditions on use" (e.g. by introducing sticky policies (Chadwick, 2008) associated with datasets, or other types of privacymetadata) and work at least at the granular level of "a logical dataset". Meeting these requirements in a generic (loosely coupled) way and with sufficient performance is challenging.
Patient consent is another important aspect which is unmistakably connected to data protection, for example with respect to re-use of personal data beyond its originally intended use (e.g. use of EHR data for automated eligibility scanning, for export for research purposes, etc.). Technically, "Consent Management Services" fit into the framework as specialised authorization services (consent rules form a policy). Such services need to ensure the integrity of consent directives and correctly combine them to avoid conflicting preferences.
Complementary to preventive security measures, the framework requires audit mechanisms allowing detection of security breaches and data leakage (and tools for subsequent incident handling).
Currently, the majority of auditing mechanisms log individual events per application or computer system. In order to reconstruct a logical chain of events for proper audit in large distributed networks, these different logs would need to be combined. Few standards and solutions are available providing manageable uniform audit trails in distributed systems.
Furthermore, to be useful for checking compliance of a (large) system with data protection legislation, audit trails need to include extended contextual information, which they rarely do (e.g. type of data accessed, identity of the person listed in the medical record accessed, etc.). Moreover, logs need to be readily accessible in a user-centric and data-centric way (e.g. be able to give an overview of activity of a single user throughout the network or the actions performed on a specific logic dataset). Reconstruction of such user-centric or data-centric audit trails based on standard logs is typically not feasible in practice: audit trail data is too large to efficiently query, identity of data subjects is not recorded or cannot be linked across applications, etc.
In order to undeniably assess the compliance of data flows with regulations, the provenance of received information and stored data must be recorded. Knowing the provenance of a data set can for example inform a user or system about the applicable data privacy policies (cf. consent). But provenance goes beyond security, and for one plays a very important role in data quality management (who is the original source, how was it recorded, cleansed, transformed, etc.).
Extended audit and provenance functionality thus comprises an important part of the technical framework.
CONCLUSIONS
The momentum gained by new initiatives focused on data sharing and collaboration 3 , 4 indicates that under the right circumstances, the biomedical community is willing to open up. We aim to support this important culture shift by building the necessary environment that will provide the needed level of semantic interoperability in full compliance with security, privacy and legal requirements.
Interoperability is by definition a global issue which cannot be successfully tackled in isolation, requiring both critical mass and openness. Therefore, to ensure a low barrier to adoption within a large community, we adopt a pragmatic approach: We rely on collaborative effort and propose a modular development of the semantic core dataset, which makes use of ontologies (e.g. SNOMED CT) and standards (e.g. HL7) that benefit of significant use in healthcare.
Our Data Protection Framework aims to provide a "unified" solution for achieving regulatory compliance (privacy & security) "by design" with minimal effort to anyone subscribing to the proposed integrating architecture.
